Delcath Systems, Inc. (NASDAQ:DCTH – Get Rating) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 157,600 shares, a drop of 7.3% from the October 15th total of 170,100 shares. Based on an average daily volume of 37,800 shares, the short-interest ratio is presently 4.2 days.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Delcath Systems by 5.7% during the 1st quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock valued at $2,309,000 after acquiring an additional 19,605 shares during the period. Cibc World Market Inc. increased its stake in Delcath Systems by 4.0% during the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares in the last quarter. CI Investments Inc. bought a new stake in Delcath Systems during the 1st quarter valued at about $559,000. Dimensional Fund Advisors LP bought a new stake in Delcath Systems during the 1st quarter valued at about $75,000. Finally, Millennium Management LLC bought a new stake in Delcath Systems during the 2nd quarter valued at about $40,000. 26.18% of the stock is owned by hedge funds and other institutional investors.
Delcath Systems Stock Performance
Shares of NASDAQ DCTH opened at $2.80 on Thursday. Delcath Systems has a 1 year low of $2.34 and a 1 year high of $10.24. The stock has a market cap of $24.07 million, a P/E ratio of -0.74 and a beta of 0.92. The firm has a 50-day moving average of $3.18 and a 200 day moving average of $3.93. The company has a debt-to-equity ratio of 2.55, a current ratio of 1.28 and a quick ratio of 1.15.
Analyst Upgrades and Downgrades
About Delcath Systems
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- Use The Airbnb Stock Implosion to Your Advantage
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- International Game Technology is Well Worth the Gamble
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.